Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis

Autor Schmeling, H, Horneff, G
Vydáno 2008

Autoimmune haemolytic anaemia in a child with MHC class II deficiency.

Autor Horneff, G, Seitz, R C, Stephan, V, Wahn, V
Vydáno 1994

Neurovascular mechanisms as a possible cause of remission of rheumatoid arthritis in hemiparetic limbs

Autor Keyszer, G, Langer, T., Kornhuber, M, Taute, B, Horneff, G
Vydáno 2004

Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children.

Autor Horneff, G, Dirksen, U, Schulze-Koops, H, Emmrich, F, Wahn, V
Vydáno 1995

Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis.

Autor Horneff, G, Sack, U, Kalden, J R, Emmrich, F, Burmester, G R
Vydáno 1993

A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

Autor Schmeling, H, Mathony, K, John, V, KeyBer, G, Burdach, S., Horneff, G
Vydáno 2001

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis

Autor Burgos-Vargas, R, Tse, S, Horneff, G, Pangan, AL, Unnebrink, K, Anderson, JK
Vydáno 2013

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis

Autor Lavric, M, Weinhage, T, Klotsche, J, Horneff, G, Haas, JP, Minden, K, Foell, D
Vydáno 2013

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis

Autor Horneff, G, Huppertz, I, Haas, P, Minden, K, Ganser, G, Hospach, A, Trauzeddel, R
Vydáno v Pediatr Rheumatol Online J (2015)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)

Autor Horneff G, Minden K, Foeldvari I, Kuemmerle-Deschner J, Thon A, Girschick H, Huppertz HI
Vydáno 2008-09-01

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)

Autor Horneff, G, Minden, K, Foeldvari, I, Kuemmerle-Deschner, J, Thon, A, Girschick, H, Huppertz, HI
Vydáno 2008

Treatment with cyclosporin A in a patient with Omenn's syndrome

Autor Meyer-Bahlburg, A, Haas, J, Haase, R, Eschrich, U, Wawer, A, Frank, L, Marsch, W, Burdach, S, Horneff, G
Vydáno 2002

PReS-FINAL-2216: Biomarkers MRP8/14 and S100A12 correspond with flare and remission clinical status in Sojia patients in the AID-NET register

Autor Gohar, F, Husmann, E, Haas, PJ, Horneff, G, Wittkowski, H, Holzinger, D, Kallinich, T, Neudorf, U, Niehues, T, Lainka, E, Foell, D
Vydáno 2013

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry

Autor Raab, A., Kallinich, T., Huscher, D., Foeldvari, I., Weller-Heinemann, F., Dressler, F., Kuemmerle-Deschner, J. B., Klein, A., Horneff, G.
Vydáno v Pediatr Rheumatol Online J (2021)

PW02-040 - Low-penetrance NLRP3 variants

Autor Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Vydáno 2013

PReS-FINAL-2331: Low-penetrance NLRP3 variants

Autor Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Vydáno 2013

PW02-041 - Canakinumab treatment regimens in CAPS-patients

Autor Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Vydáno 2013

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients

Autor Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schütz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Vydáno 2013

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

Autor Horneff, G, Fitter, S, Huppertz, HI, Foeldvari, I, Kuemmerle-Deschner, K, Kuester, R, Tzaribacev, N, Thon, A, Borte, M, Ganser, G, Trauzeddel, R, Minden, K
Vydáno 2011

Canakinumab treat-to target strategies increase complete response rate in CAPS

Autor Kuemmerle-Deschner, J, Hofer, F, Endres, T, Kortus-Goetze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Benseler, SM
Vydáno v Pediatr Rheumatol Online J (2015)